knowledge -WSS

knowledge

author：knowledge 2025-09-06 03:32:40 - browse：79

Adam's take main illustration — Molly Ferguson/STAT

This week, an encouraging turnaround for Ocular Therapeutix, a chat with Alnylam’s CEO defending changes to the HELIOS-B study and talking up its hypertension treatment, and quick takes on Amylyx and obesity stocks.

A Worst CEO gets some much-needed help

For most of last year, Ocular Therapeutix CEO Antony Mattessich promised shareholders that he was close to nailing down a lucrative pharma partnership that would pay for late-stage clinical trials of the company’s treatments for degenerative eye diseases. The deal never happened. I heard from many Ocular investors who were frustrated and angry about Mattesich’s poor job performance. He ended up earning a spot last year on my worst biopharma CEO list. It was an easy pick.

On Thursday, Ocular announced a meaningful “leadership update.” Mattessich is still the CEO, but let’s just say the company’s board decided to surround him with new executives and retinal experts with proven track records of getting stuff done.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Hospitals look to new technology to keep health care workers safe

Wikipedia

WSS

Anthos stroke drug appears safer than common blood thinner

Akero's treatment for NASH falls short in cirrhosis study

How clinical AI models' predictive power can degrade over time

Life sciences deals on track to hit lowest point since 2017

A daunting task: navigating dual Medicare, Medicaid eligibility

A revolution in caring for preterm infants

Wikipedia

knowledge

A Worst CEO gets some much-needed help

focus

Trump demands the U.S. pay no more for drugs than other countries … again

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

Activists slam private health insurers over coverage restrictions

Surge of respiratory disease in China has likely explanation

Supreme Court strikes down use of affirmative action

Surge of respiratory disease in China has likely explanation

At least 13 dead in Texas as scorching temps continue

European regulators recommend Amylyx's ALS drug be rejected

After affirmative action ruling, medical educators look to 'holistic review'

Akero's treatment for NASH falls short in cirrhosis study

leisure time

Readout LOUD podcast: Merger Mondays, Ozempic panic

Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

A fraught question for the kids of Alzheimer’s: Is it coming for us?

Astellas still sees hope in its gene therapy after four deaths

Hospitals look to new technology to keep health care workers safe

PBM reforms clear House panel

leisure time

Wikipedia

Wikipedia

hotspot